SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Biotechnology

Healthcare
$29.68 +2.49%

+$0.45 today

Market cap
$993.14M
Beta
-0.34
P/E (TTM)
-14.1
EPS (TTM)
-$1.32
52W Low $17.06High $32.44

Volume 0.10M

Average 0.09M

SGP Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

SpyGlass Pharma, Inc. Common StockNASDAQ: SGP

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables of $653K in Q1 FY2026

Q1 FY2026 net receivables was $653K.

Context

  • Net receivables amounted to 0.3% of total assets at the end of Q1 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$653K+51.5% QoQ
Last fiscal yearDec 2025
$431K— YoY
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
431K USD
Year-over-year change
—

Net Receivables vs competitors

How SGP compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Net receivables amounts to 0.3% of total assets for SGP, versus a peer median of 7.4%.
SGP Competitors
Net Receivables for SGP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALCAlcon Inc.Sep 2026$2.07B USD+6.6%-0.8%6.6%
BLCOBausch + Lomb CorporationJun 2026$1.16B USD+6.6%+18.9%8.4%
GKOSGlaukos CorporationJun 2026$138.9M USD+67.4%+44.4%15.1%
STAASTAAR Surgical CompanyApr 2026$85.69M USD+100.7%-6.1%19.0%
OCULOcular Therapeutix, Inc.Mar 2026$24.35M USD-3.5%+12.9%3.3%
RXSTRxSight, Inc.Mar 2026$22.44M USD-27.5%+28.8%7.4%
SGHTSight Sciences, Inc.Mar 2026$10.6M USD+12.4%-13.7%9.7%
OCSOculis Holding AGMar 2026CHF 1.57M CHF-38.7%—0.6%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$1.16M USD+161.8%-65.2%0.4%
SGPSpyGlass Pharma, Inc. Common StockMar 2026$653K USD——0.3%
Peer median (excluding SGP) —+6.6%+6.0%7.4%

Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.